drugset
drugset / Trial / NCT01231633

Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)

NCT01231633 ↗

Completed 27 enrolled Long Island Vitreoretinal Consultants
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to compare visual improvement and total number of intraocular injections in eyes with macular edema following central retinal vein occlusion (CRVO)after initial treatment with Ozurdex (dexamethasone implant) or Avastin (bevacizumab).

Timeline

Start
2010-09
Primary completion
2014-09
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 1.25 mg Intravitreal
Subject Dexamethasone Small molecule 0.7 mg —

Indications

central retinal vein occlusion macular retinal edema